Recent insights into CD4⁺ T-cell specificity and function in Type 1 diabetes

References

• Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N. Engl. J. Med.331(21), 1428–1436 (1994).
   PubMed Web of Science ®Google Scholar
• Harrison LC. Risk assessment, prediction and prevention of Type 1 diabetes. Pediatr. Diabetes2(2), 71–82 (2001).
   PubMedGoogle Scholar
• Serreze DV, Leiter EH. Genes and cellular requirements for autoimmune diabetes susceptibility in nonobese diabetic mice. Curr. Dir. Autoimmun.4, 31–67 (2001).
   PubMedGoogle Scholar
• Shoda LK, Young DL, Ramanujan S et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity23(2), 115–126 (2005).
   PubMed Web of Science ®Google Scholar
• Maier LM, Wicker LS. Genetic susceptibility to Type 1 diabetes. Curr. Opin. Immunol.17(6), 601–608 (2005).
   PubMed Web of Science ®Google Scholar
• Papaccio G. Insulitis and islet microvasculature in Type 1 diabetes. Histol. Histopathol.8(4), 751–759 (1993).
   PubMed Web of Science ®Google Scholar
• Bendelac A, Carnaud C, Boitard C, Bach JF. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells. J. Exp. Med.166(4), 823–832 (1987).
   PubMed Web of Science ®Google Scholar
• Haskins K, McDuffie M. Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone. Science249(4975), 1433–1436 (1990).
   PubMed Web of Science ®Google Scholar
• Serreze DV, Chapman HD, Varnum DS et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new “speed congenic” stock of NOD.Ig µ null mice. J. Exp. Med.184(5), 2049–2053 (1996).
   PubMed Web of Science ®Google Scholar
• Silveira PA, Grey ST. B cells in the spotlight: innocent bystanders or major players in the pathogenesis of Type 1 diabetes. Trends Endocrinol. Metab.17(4), 128–135 (2006).
   PubMed Web of Science ®Google Scholar
• Lampeter EF, McCann SR, Kolb H. Transfer of diabetes Type 1 by bone-marrow transplantation. Lancet351(9102), 568–569 (1998).
   PubMed Web of Science ®Google Scholar
• Martin S, Wolf-Eichbaum D, Duinkerken G et al. Development of Type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N. Engl. J. Med.345(14), 1036–1040 (2001).
   PubMed Web of Science ®Google Scholar
• Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am. J. Hum. Genet.59(5), 1134–1148 (1996).
   PubMed Web of Science ®Google Scholar
• Pugliese A, Eisenbarth GS. Human Type 1 diabetes mellitus: genetic susceptiblity and resistance. In: Type 1 Diabetes. Molecular, Cellular, and Clinical Immunology. Eisenbarth GS, Lafferty KJ (Eds.). Oxford University Press, NY, USA, and Oxford, UK 134–152 (1996).
   Google Scholar
• Ridgway WM, Fathman CG. MHC structure and autoimmune T cell repertoire development. Curr. Opin. Immunol.11(6), 638–642 (1999).
   PubMedGoogle Scholar
• Sheehy MJ, Scharf SJ, Rowe JR et al. A diabetes-susceptible HLA haplotype is best defined by a combination of HLA-DR and -DQ alleles. J. Clin. Invest.83(3), 830–835 (1989).
   PubMed Web of Science ®Google Scholar
• Tomlinson IP, Bodmer WF. The HLA system and the analysis of multifactorial genetic disease. Trends Genet.11(12), 493–498. (1995).
   PubMedGoogle Scholar
• Todd JA, Bell JI, McDevitt HO. HLA-DQ β gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature329(6140), 599–604 (1987).
   PubMed Web of Science ®Google Scholar
• Owerbach D, Gabbay KH. Localization of a Type I diabetes susceptibility locus to the variable tandem repeat region flanking the insulin gene. Diabetes42(12), 1708–1714 (1993).
   PubMedGoogle Scholar
• Vang T, Congia M, Macis MD et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet.37(12), 1317–1319 (2005).
   PubMed Web of Science ®Google Scholar
• Ueda H, Howson JM, Esposito L et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature423(6939), 506–511 (2003).
   PubMed Web of Science ®Google Scholar
• Morahan G, Huang D, Ymer SI et al. Linkage disequilibrium of a Type 1 diabetes susceptibility locus with a regulatory IL12B allele. Nat. Genet.27(2), 218–221 (2001).
   PubMed Web of Science ®Google Scholar
• Vella A, Cooper JD, Lowe CE et al. Localization of a Type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am. J. Hum. Genet.76(5), 773–779 (2005).
   PubMed Web of Science ®Google Scholar
• Pugliese A, Zeller M, Fernandez A Jr et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for Type 1 diabetes. Nat. Genet.15(3), 293–297 (1997).
   PubMed Web of Science ®Google Scholar
• Bennett ST, Lucassen AM, Gough SC et al. Susceptibility to human Type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat. Genet.9(3), 284–292 (1995).
   PubMed Web of Science ®Google Scholar
• Vafiadis P, Bennett ST, Todd JA et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat. Genet.15(3), 289–292 (1997).
   PubMed Web of Science ®Google Scholar
• Bottini N, Vang T, Cucca F, Mustelin T. Role of PTPN22 in Type 1 diabetes and other autoimmune diseases. Semin. Immunol.18(4), 207–213 (2006).
   PubMed Web of Science ®Google Scholar
• Boden E, Tang Q, Bour-Jordan H, Bluestone JA. The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells. Novartis Found. Symp.252, 55–63; discussion 63–56, 106–114 (2003).
   PubMedGoogle Scholar
• Cooper AM, Khader SA. IL-12p40: an inherently agonistic cytokine. Trends Immunol.28(1), 33–38 (2007).
   PubMed Web of Science ®Google Scholar
• Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol.4(9), 665–674 (2004).
   PubMed Web of Science ®Google Scholar
• Haskins K. Pathogenic T-cell clones in autoimmune diabetes: more lessons from the NOD mouse. Adv. Immunol.87, 123–162 (2005).
   PubMed Web of Science ®Google Scholar
• Di Lorenzo TP, Peakman M, Roep BO. Translational mini-review series on Type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes. Clin. Exp. Immunol.148(1), 1–16 (2007).
   PubMedGoogle Scholar
• Nakayama M, Abiru N, Moriyama H et al. Prime role for an insulin epitope in the development of Type 1 diabetes in NOD mice. Nature435(7039), 220–223 (2005).
   PubMed Web of Science ®Google Scholar
• Krishnamurthy B, Dudek NL, McKenzie MD et al. Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J. Clin. Invest.116(12), 3258–3265 (2006).
   PubMed Web of Science ®Google Scholar
• Baker FJ, Lee M, Chien YH, Davis MM. Restricted islet-cell reactive T cell repertoire of early pancreatic islet infiltrates in NOD mice. Proc. Natl Acad. Sci. USA99(14), 9374–9379 (2002).
   PubMedGoogle Scholar
• Gelber C, Paborsky L, Singer S et al. Isolation of nonobese diabetic mouse T-cells that recognize novel autoantigens involved in the early events of diabetes. Diabetes43(1), 33–39 (1994).
   PubMedGoogle Scholar
• Brooks-Worrell BM, Starkebaum GA, Greenbaum C, Palmer JP. Peripheral blood mononuclear cells of insulin-dependent diabetic patients respond to multiple islet cell proteins. J. Immunol.157(12), 5668–5674 (1996).
   PubMedGoogle Scholar
• Mannering SI, Purcell AW, Honeyman MC, McCluskey J, Harrison LC. Human T-cells recognise N-terminally Fmoc-modified peptide. Vaccine21(25–26), 3638–3646 (2003).
   PubMed Web of Science ®Google Scholar
• Nagvekar N, Corlett L, Jacobson LW et al. Scanning a DRB3*0101 (DR52a)-restricted epitope cross-presented by DR3: overlapping natural and artificial determinants in the human acetylcholine receptor. J. Immunol.162(7), 4079–4087. (1999).
   PubMed Web of Science ®Google Scholar
• Engelhard VH, Altrich-Vanlith M, Ostankovitch M, Zarling AL. Post-translational modifications of naturally processed MHC-binding epitopes. Curr. Opin. Immunol.18(1), 92–97 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson RP, Degano P, Godkin AJ, Jewell DP, Hill AV. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat. Med.6(3), 337–342. (2000).
   PubMed Web of Science ®Google Scholar
• Molberg O, McAdam SN, Korner R et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat. Med.4(6), 713–717. (1998).
   PubMed Web of Science ®Google Scholar
• Girbal-Neuhauser E, Durieux JJ, Arnaud M et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J. Immunol.162(1), 585–594 (1999).
   PubMed Web of Science ®Google Scholar
• Kent SC, Chen Y, Bregoli L et al. Expanded T cells from pancreatic lymph nodes of Type 1 diabetic subjects recognize an insulin epitope. Nature435(7039), 224–228 (2005).
   PubMed Web of Science ®Google Scholar
• Mannering SI, Harrison LC, Williamson NA et al. The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J. Exp. Med.202(9), 1191–1197 (2005).
   PubMed Web of Science ®Google Scholar
• You S, Thieblemont N, Alyanakian MA, Bach JF, Chatenoud L. Transforming growth factor-β and T-cell-mediated immunoregulation in the control of autoimmune diabetes. Immunol. Rev.212, 185–202 (2006).
   PubMed Web of Science ®Google Scholar
• Tang Q, Bluestone JA. Regulatory T-cell physiology and application to treat autoimmunity. Immunol. Rev.212, 217–237 (2006).
   PubMed Web of Science ®Google Scholar
• Suri-Payer E, Fritzsching B. Regulatory T cells in experimental autoimmune disease. Springer Semin. Immunopathol.28(1), 3–16 (2006).
   PubMedGoogle Scholar
• Tang Q, Henriksen KJ, Bi M et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med.199(11), 1455–1465 (2004).
   PubMed Web of Science ®Google Scholar
• Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med.199(11), 1467–1477 (2004).
   PubMed Web of Science ®Google Scholar
• Masteller EL, Warner MR, Tang Q, Tarbell KV, McDevitt H, Bluestone JA. Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J. Immunol.175(5), 3053–3059 (2005).
   PubMed Web of Science ®Google Scholar
• Tarbell KV, Petit L, Zuo X et al. Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J. Exp. Med.204(1), 191–201 (2007).
   PubMed Web of Science ®Google Scholar
• French MB, Allison J, Cram DS et al. Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice. Diabetes46(1), 34–39 (1997).
   PubMedGoogle Scholar
• Steptoe RJ, Ritchie JM, Harrison LC. Transfer of hematopoietic stem cells encoding autoantigen prevents autoimmune diabetes. J. Clin. Invest.111(9), 1357–1363 (2003).
   PubMed Web of Science ®Google Scholar
• Brusko T, Wasserfall C, McGrail K et al. No alterations in the frequency of FOXP3+ regulatory T-cells in Type 1 diabetes. Diabetes56(3), 604–612 (2007).
   PubMed Web of Science ®Google Scholar
• Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4+CD25+ T-cells from patients with Type 1 diabetes. Diabetes54(1), 92–99 (2005).
   PubMed Web of Science ®Google Scholar
• Glisic-Milosavljevic S, Waukau J, Jailwala P et al. At-risk and recent-onset Type 1 diabetic subjects have increased apoptosis in the CD4+CD25+ T-cell fraction. PLoS ONE2, e146 (2007).
   PubMed Web of Science ®Google Scholar
• Tiittanen M, Huupponen JT, Knip M, Vaarala O. Insulin treatment in patients with Type 1 diabetes induces upregulation of regulatory T-cell markers in peripheral blood mononuclear cells stimulated with insulin in vitro. Diabetes55(12), 3446–3454 (2006).
   PubMedGoogle Scholar
• Tree TI, Duinkerken G, Willemen S, de Vries RR, Roep BO. HLA-DQ-regulated T-cell responses to islet cell autoantigens insulin and GAD65. Diabetes53(7), 1692–1699 (2004).
   PubMedGoogle Scholar
• Seyfert-Margolis V, Gisler TD, Asare AL et al. Analysis of T-cell assays to measure autoimmune responses in subjects with Type 1 diabetes: results of a blinded controlled study. Diabetes55(9), 2588–2594 (2006).
   PubMedGoogle Scholar
• Bingley PJ, Williams AJ, Gale EA. Optimized autoantibody-based risk assessment in family members. Implications for future intervention trials. Diabetes Care22(11), 1796–1801 (1999).
   PubMedGoogle Scholar
• Meierhoff G, Ott PA, Lehmann PV, Schloot NC. Cytokine detection by ELISPOT: relevance for immunological studies in Type 1 diabetes. Diabetes Metab. Re.s Rev.18(5), 367–380. (2002).
   PubMedGoogle Scholar
• Schloot NC, Meierhoff G, Karlsson Faresjo M et al. Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology of diabetes society T-cell workshop. J. Autoimmun.21(4), 365–376 (2003).
   PubMed Web of Science ®Google Scholar
• Kotani R, Nagata M, Moriyama H et al. Detection of GAD65-reactive T-cells in Type 1 diabetes by immunoglobulin-free ELISPOT assays. Diabetes Care25(8), 1390–1397 (2002).
   PubMed Web of Science ®Google Scholar
• Ott PA, Berner BR, Herzog BA et al. CD28 costimulation enhances the sensitivity of the ELISPOT assay for detection of antigen-specific memory effector CD4 and CD8 cell populations in human diseases. J. Immunol. Methods285(2), 223–235 (2004).
   PubMedGoogle Scholar
• Arif S, Tree TI, Astill TP et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest.113(3), 451–463 (2004).
   PubMed Web of Science ®Google Scholar
• Alleva DG, Crowe PD, Jin L et al. A disease-associated cellular immune response in Type 1 diabetics to an immunodominant epitope of insulin. J. Clin. Invest.107(2), 173–180. (2001).
   PubMed Web of Science ®Google Scholar
• Ott PA, Herzog BA, Quast S et al. Islet-cell antigen-reactive T cells show different expansion rates and Th1/Th2 differentiation in type 1 diabetic patients and healthy controls. Clin. Immunol.115(1), 102–114 (2005).
   PubMedGoogle Scholar
• Ott PA, Dittrich MT, Herzog BA et al. T cells recognize multiple gad65 and proinsulin epitopes in human Type 1 diabetes, suggesting determinant spreading. J. Clin. Immunol.24(4), 327–339 (2004).
   PubMedGoogle Scholar
• Endl J, Rosinger S, Schwarz B et al. Coexpression of CD25 and OX40 (CD134) receptors delineates autoreactive T-cells in Type 1 diabetes. Diabetes55(1), 50–60 (2006).
   PubMedGoogle Scholar
• Baker C, Chang L, Elsegood KA et al. Activated T cell subsets in human Type 1 diabetes: evidence for expansion of the DR+ CD30+ subpopulation in new-onset disease. Clin. Exp. Immunol.147(3), 472–482 (2007).
   PubMedGoogle Scholar
• Kwok WW, Ptacek NA, Liu AW, Buckner JH. Use of class II tetramers for identification of CD4+ T cells. J. Immunol. Methods268(1), 71–81 (2002).
   PubMed Web of Science ®Google Scholar
• Mallone R, Nepom GT. MHC Class II tetramers and the pursuit of antigen-specific T cells: define, deviate, delete. Clin. Immunol.110(3), 232–242 (2004).
   PubMedGoogle Scholar
• Yang J, Danke NA, Berger D et al. Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects. J. Immunol.176(5), 2781–2789 (2006).
   PubMed Web of Science ®Google Scholar
• Reijonen H, Novak EJ, Kochik S et al. Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in Type 1 diabetic patients and at-risk subjects. Diabetes51(5), 1375–1382. (2002).
   PubMedGoogle Scholar
• Danke NA, Yang J, Greenbaum C, Kwok WW. Comparative study of GAD65-specific CD4+ T cells in healthy and Type 1 diabetic subjects. J. Autoimmun.25(4), 303–311 (2005).
   PubMedGoogle Scholar
• Oling V, Marttila J, Ilonen J et al. GAD65-and proinsulin-specific CD4+ T-cells detected by MHC class II tetramers in peripheral blood of Type 1 diabetes patients and at-risk subjects. J. Autoimmun.25(3), 235–243 (2005).
   PubMedGoogle Scholar
• Mallone R, Kochik SA, Laughlin EM et al. Differential recognition and activation thresholds in human autoreactive GAD-specific T-cells. Diabetes53(4), 971–977 (2004).
   PubMedGoogle Scholar
• Mallone R, Kochik SA, Reijonen H et al. Functional avidity directs T-cell fate in autoreactive CD4+ T cells. Blood106(8), 2798–2805 (2005).
   PubMedGoogle Scholar
• Preda-Pais A, Stan AC, Casares S, Bona C, Brumeanu TD. Efficacy of clonal deletion vs. anergy of self-reactive CD4 T-cells for the prevention and reversal of autoimmune diabetes. J. Autoimmun.25(1), 21–32 (2005).
   PubMedGoogle Scholar
• Preda I, McEvoy RC, Lin M et al. Soluble, dimeric HLA DR4–peptide chimeras: an approach for detection and immunoregulation of human type-1 diabetes. Eur. J. Immunol.35(9), 2762–2775 (2005).
   PubMed Web of Science ®Google Scholar
• Kwok WW, Gebe JA, Liu A et al. Rapid epitope identification from complex class-II-restricted T-cell antigens. Trends Immunol.22(11), 583–588. (2001).
   PubMed Web of Science ®Google Scholar
• Dosch H, Cheung RK, Karges W, Pietropaolo M, Becker DJ. Persistent T cell anergy in human Type 1 diabetes. J. Immunol.163(12), 6933–6940. (1999).
   PubMed Web of Science ®Google Scholar
• Mannering SI, Morris JS, Jensen KP et al. A sensitive method for detecting proliferation of rare autoantigen-specific human T cells. J. Immunol. Methods283(1–2), 173–183 (2003).
   PubMed Web of Science ®Google Scholar
• Mannering SI, Dromey JA, Morris JS, Thearle DJ, Jensen KP, Harrison LC. An efficient method for cloning human autoantigen-specific T cells. J. Immunol. Methods298(1–2), 83–92 (2005).
   PubMedGoogle Scholar
• Turcanu V, Maleki SJ, Lack G. Characterization of lymphocyte responses to peanuts in normal children, peanut-allergic children, and allergic children who acquired tolerance to peanuts. J. Clin. Invest.111(7), 1065–1072 (2003).
   PubMed Web of Science ®Google Scholar